The University of Chicago Header Logo

Connection

George Bakris to Albuminuria

Back to Details
This is a "connection" page, showing publications George Bakris has written about Albuminuria.
George Bakris
Connection Strength
15.941
Albuminuria
  1. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
    View in: PubMed
    Score: 0.661
  2. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306.
    View in: PubMed
    Score: 0.509
  3. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43.
    View in: PubMed
    Score: 0.509
  4. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
    View in: PubMed
    Score: 0.496
  5. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
    View in: PubMed
    Score: 0.474
  6. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6.
    View in: PubMed
    Score: 0.452
  7. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
    View in: PubMed
    Score: 0.442
  8. A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique? J Hypertens. 2012 Jan; 30(1):48-50.
    View in: PubMed
    Score: 0.385
  9. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010 Sep; 8(5):604-11.
    View in: PubMed
    Score: 0.351
  10. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70.
    View in: PubMed
    Score: 0.342
  11. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43.
    View in: PubMed
    Score: 0.331
  12. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med. 2009 Jul; 121(4):51-60.
    View in: PubMed
    Score: 0.323
  13. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63.
    View in: PubMed
    Score: 0.305
  14. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.296
  15. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9.
    View in: PubMed
    Score: 0.290
  16. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85.
    View in: PubMed
    Score: 0.283
  17. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertens (Greenwich). 2007 Mar; 9(3):196-200.
    View in: PubMed
    Score: 0.275
  18. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
    View in: PubMed
    Score: 0.267
  19. Microalbuminuria. Clin Lab Med. 2006 Sep; 26(3):635-53, vi-vii.
    View in: PubMed
    Score: 0.266
  20. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006 Sep; 21(9):2366-74.
    View in: PubMed
    Score: 0.262
  21. Albuminuria and cardiovascular risk. Heart Fail Clin. 2006 Jan; 2(1):53-9.
    View in: PubMed
    Score: 0.254
  22. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15.
    View in: PubMed
    Score: 0.251
  23. Inclusion of albuminuria in hypertension and heart guidelines. Kidney Int Suppl. 2004 Nov; (92):S124-5.
    View in: PubMed
    Score: 0.234
  24. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):8-12.
    View in: PubMed
    Score: 0.234
  25. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):18-22.
    View in: PubMed
    Score: 0.234
  26. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
    View in: PubMed
    Score: 0.233
  27. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741.
    View in: PubMed
    Score: 0.215
  28. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
    View in: PubMed
    Score: 0.206
  29. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep. 2002 Jun; 2(3):258-62.
    View in: PubMed
    Score: 0.198
  30. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91.
    View in: PubMed
    Score: 0.194
  31. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002 Feb; 7(1):35-43.
    View in: PubMed
    Score: 0.193
  32. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585.
    View in: PubMed
    Score: 0.192
  33. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70.
    View in: PubMed
    Score: 0.190
  34. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
    View in: PubMed
    Score: 0.189
  35. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 08 26; 2(8):1240-1250.
    View in: PubMed
    Score: 0.186
  36. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001 Mar-Apr; 3(2):99-102.
    View in: PubMed
    Score: 0.181
  37. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
    View in: PubMed
    Score: 0.181
  38. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
    View in: PubMed
    Score: 0.173
  39. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149.
    View in: PubMed
    Score: 0.173
  40. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 04; 22 Suppl 1:69-76.
    View in: PubMed
    Score: 0.170
  41. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
    View in: PubMed
    Score: 0.155
  42. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications. 1997 Nov-Dec; 11(6):352-7.
    View in: PubMed
    Score: 0.144
  43. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374.
    View in: PubMed
    Score: 0.142
  44. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55.
    View in: PubMed
    Score: 0.136
  45. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4.
    View in: PubMed
    Score: 0.132
  46. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996 May; 5(3):219-23.
    View in: PubMed
    Score: 0.130
  47. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9.
    View in: PubMed
    Score: 0.128
  48. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49.
    View in: PubMed
    Score: 0.118
  49. Microalbuminuria and progressive renal disease. J Hum Hypertens. 1994 Nov; 8(11):809-17.
    View in: PubMed
    Score: 0.117
  50. Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival. Arch Intern Med. 1994 Jan 24; 154(2):146-53.
    View in: PubMed
    Score: 0.111
  51. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6.
    View in: PubMed
    Score: 0.110
  52. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73.
    View in: PubMed
    Score: 0.092
  53. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56.
    View in: PubMed
    Score: 0.092
  54. Renal function and target organ damage in hypertension. Eur Heart J. 2011 Jul; 32(13):1599-604.
    View in: PubMed
    Score: 0.091
  55. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10.
    View in: PubMed
    Score: 0.089
  56. Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP). Diabetes Care. 2010 Dec; 33(12):2586-91.
    View in: PubMed
    Score: 0.088
  57. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86.
    View in: PubMed
    Score: 0.087
  58. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010 Jun; 12(6):422-30.
    View in: PubMed
    Score: 0.086
  59. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.084
  60. Prehypertension: is it relevant for nephrologists? Kidney Int. 2010 Feb; 77(3):194-200.
    View in: PubMed
    Score: 0.083
  61. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42.
    View in: PubMed
    Score: 0.083
  62. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl. 2009 Jul; 27(5):S15-21.
    View in: PubMed
    Score: 0.081
  63. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
    View in: PubMed
    Score: 0.079
  64. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):444-52.
    View in: PubMed
    Score: 0.076
  65. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9.
    View in: PubMed
    Score: 0.075
  66. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.066
  67. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006; 1(3):209-14; quiz 215-6.
    View in: PubMed
    Score: 0.063
  68. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005 Apr; 18(4 Pt 2):112S-119S.
    View in: PubMed
    Score: 0.060
  69. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.060
  70. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
    View in: PubMed
    Score: 0.059
  71. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004 May-Jun; 24(3):284-8.
    View in: PubMed
    Score: 0.056
  72. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol. 2004 Apr; 44(4):431-8.
    View in: PubMed
    Score: 0.056
  73. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
    View in: PubMed
    Score: 0.055
  74. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.
    View in: PubMed
    Score: 0.055
  75. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003 Oct; 5(5):418-25.
    View in: PubMed
    Score: 0.054
  76. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22.
    View in: PubMed
    Score: 0.054
  77. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383.
    View in: PubMed
    Score: 0.052
  78. When to refer patients to a nephrologist? Postgrad Med. 2003 Feb; 113(2):11.
    View in: PubMed
    Score: 0.052
  79. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 01 24; 81(3):270-282.
    View in: PubMed
    Score: 0.052
  80. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
    View in: PubMed
    Score: 0.051
  81. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695.
    View in: PubMed
    Score: 0.051
  82. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 11; 10(11):860-870.
    View in: PubMed
    Score: 0.051
  83. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002 May; 39(5):899-919.
    View in: PubMed
    Score: 0.049
  84. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400.
    View in: PubMed
    Score: 0.049
  85. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079.
    View in: PubMed
    Score: 0.049
  86. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 12; 16(12):1824-1832.
    View in: PubMed
    Score: 0.048
  87. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263.
    View in: PubMed
    Score: 0.047
  88. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
    View in: PubMed
    Score: 0.045
  89. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568.
    View in: PubMed
    Score: 0.045
  90. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
    View in: PubMed
    Score: 0.044
  91. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
    View in: PubMed
    Score: 0.043
  92. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806.
    View in: PubMed
    Score: 0.042
  93. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018 12 19; 8(12):e021038.
    View in: PubMed
    Score: 0.039
  94. Risks for renal involvement in diabetes. Postgrad Med. 1998 Sep; 104(3):33.
    View in: PubMed
    Score: 0.038
  95. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704.
    View in: PubMed
    Score: 0.033
  96. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8.
    View in: PubMed
    Score: 0.028
  97. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993 Apr 26; 153(8):973-80.
    View in: PubMed
    Score: 0.026
  98. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4.
    View in: PubMed
    Score: 0.026
  99. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7.
    View in: PubMed
    Score: 0.024
  100. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):e1-e47.
    View in: PubMed
    Score: 0.023
  101. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
    View in: PubMed
    Score: 0.022
  102. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
    View in: PubMed
    Score: 0.018
  103. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9.
    View in: PubMed
    Score: 0.018
  104. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90.
    View in: PubMed
    Score: 0.016
  105. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.